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ABSTRACT
A significant number of X-linked genes escape
from X chromosome inactivation and are associ-
ated with a distinct epigenetic signature. One epi-
genetic modification that strongly correlates with X-
escape is reduced DNA methylation in promoter re-
gions. Here, we created an artificial escape by editing
DNA methylation on the promoter of CDKL5, a gene
causative for an infantile epilepsy, from the silenced
X-chromosomal allele in human neuronal-like cells.
We identify that a fusion of the catalytic domain of
TET1 to dCas9 targeted to the CDKL5 promoter us-
ing three guide RNAs causes significant reactivation
of the inactive allele in combination with removal of
methyl groups from CpG dinucleotides. Strikingly, we
demonstrate that co-expression of TET1 and a VP64
transactivator have a synergistic effect on the reacti-
vation of the inactive allele to levels >60% of the ac-
tive allele. We further used a multi-omics assessment
to determine potential off-targets on the transcrip-
tome and methylome. We find that synergistic deliv-
ery of dCas9 effectors is highly selective for the tar-
get site. Our findings further elucidate a causal role
for reduced DNA methylation associated with escape
from X chromosome inactivation. Understanding the
epigenetics associated with escape from X chromo-
some inactivation has potential for those suffering
from X-linked disorders.
INTRODUCTION
Epigenetics is the study of mitotically and/or meiotically
stable but reversible modifications to nucleotides or higher
order chromatin structure that can alter expression patterns
of genes in the absence of changes to the underlying DNA
sequence (1). These modifications occur on multiple lev-
els, such as 5-methyl-cytosine (5-meC) DNA methylation,
post-translational modifications of histones bound by pro-
tein domains that serve as epigenetic writers, readers and
erasers and noncoding RNAs that assist in the recruitment
of chromatin modifying proteins to DNA (2). These epige-
netic layers dynamically dictate the three-dimensional or-
ganization of the genome within the nuclear ultrastructure
and orchestrate local accessibility for the eukaryotic tran-
scriptional machinery (3). Because of this, epigenetic signa-
tures play a crucial role in dictating cellular identity during
development and throughout life in response to the envi-
ronment (1), correlate with aging (4) and are linked to dis-
ease (5). The process of X-chromosome inactivation (XCI)
epigenetically regulates the amount of transcriptionally ac-
tive X-chromatin in somatic tissue as a dosage compen-
sation mechanism to ensure equal expression levels of X-
linked genes in males and females (6). In female somatic
cells, one X chromosome randomly becomes inactive and is
cytologically manifested during interphase as a perinuclear
heterochromatic Barr body, which is then clonally main-
tained through mitosis (7,8). This mechanism is mediated
by the long noncoding RNA X-inactive specific transcript
(XIST) expressed from the inactive X chromosome in cis
(9), which serves as a guiding factor to tether Polycomb pro-
teins for gene silencing to target sites on the X-chromatin
(10). XIST induces the formation of repressive heterochro-
matin through histone deacetylation (11), DNA methyla-
tion of CpG-island (CGI) promoters (12), di- and trimethy-
lation of histone 3 at lysine 9 (H3K9me2/3) (13), the de-
position and spreading of H3K27me3 across the inactive
X-chromatin (14) and the H2A histone variant macroH2A
(15).
*To whom correspondence should be addressed. Tel: +1 916 703 9368; Fax: +1 916 703 9310; Email: kdfink@ucdavis.edu
C© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz1214/5700548 by Serials R
ecords Section,  kdfink@
ucdavis.edu on 14 January 2020
2 Nucleic Acids Research, 2020
Interestingly, gene expression data suggests there is an es-
timated 15–30% of human X-linked genes that escape XCI
(16) at an arbitrary transcriptional threshold of 10% of the
active allele (17). The level of escape fromXCI is variable be-
tween genes and individuals (16), demonstrates tissue het-
erogeneity (18) and increases with age (19). Strikingly, X-
escapees have a distinct epigenetic signature from genes that
are subject to XCI, including enrichment of active and de-
pletion of repressive histone marks, and generally reduced
levels of DNA methylation near regulatory elements (17).
In particular, the degree of CGI promoter 5-meC DNA
methylation has been demonstrated to be highly correlative
with XCI (12,20). In line with the idea that DNA methy-
lation forms an epigenetic barrier on the inactive X chro-
mosome, the most potent X-reactivation to date has been
achieved by treatment with 5-azacytidine, a globalDNAhy-
pomethylating agent in combination with X-wide genetic
ablation of XIST (21). In addition, pharmacological and
genetic screens aiming to identify trans-acting factors pro-
moting XCI have identified the maintenance DNA methyl-
transferase DNMT1 as a key player in XCI (22,23). How-
ever, previous studies aiming to elucidate the mechanism of
XCI-escape, such as the aforementioned small molecule ap-
proaches, utilized untargeted approaches. While these stud-
ies have provided a significant foundation of knowledge, in
particular demonstrating the importance of DNA methy-
lation in our understanding of X-reactivation, the global
side-effects of these types of approaches limit the study of
specific gene reactivation. In order to further our under-
standing of XCI and reactivation of X-linked genes, tar-
geted approaches that result in specific gene reactivation are
required.
Until recently, the lack of targeted approaches by which
we can modify epigenetics has limited the ways in which
we can understand mechanisms of XCI. With the avail-
ability of the RNA-guided clustered regularly interspaced
palindromic repeats (CRISPR) system, catalytically inac-
tive dCas9 fused to epigenetic effector domains has be-
come the method of choice for targeted rewriting of the
epigenome to further elucidate the causality between epi-
genetic marks and gene expression (24,25). Recently, dCas9
fusions with the catalytic domain of ten-eleven transloca-
tion dioxygenase 1 (TET1) have gained prominence as a
candidate to precisely demethylate gene promoters or en-
hancers for multiple gene targets (26–29). Targeted DNA
demethylation of genes on the X chromosome would allow
for a directed assessment of the causal role between DNA
methylation and gene expression on the inactive X chromo-
some. Furthermore, the presence of coding SNPs that ex-
ist in clonally-derived female cell lines provides an allele-
specific model to study escape from XCI induced by tar-
geted epigenetic remodelling.
The neurodevelopmental disorder CDKL5 deficiency is
caused by de novo mutations in the CDKL5 gene on the
X chromosome (30). Due to random XCI, females affected
by the disorder form a mosaic of tissue with cells express-
ing either the mutant or wild type allele (31). A potential
therapeutic approach might be to activate the silenced wild
type CDKL5 allele in cells expressing the loss-of-function
mutant allele. Here, we sought to synthetically induce es-
cape of CDKL5 from the inactive X chromosome in the
neuronal-like cell line SH-SY5Y. DNA methylation edit-
ing of the CDKL5 promoter using a dCas9-TET1 fusion
protein for targeted DNA demethylation was found to re-
sult in a significant increase in allele-specific expression of
the inactive allele and is correlated with a significant re-
duction in methylated CpG dinucleotides in the CGI core
promoter. We also demonstrate that TET1 has a synergis-
tic effect with the transcriptional activator VP64, thereby
further increasing transcript levels from the inactive allele.
As such, our study demonstrates that loss of DNAmethyla-
tion is crucial for inducing escape from the inactive X chro-
mosome. Finally, we confirmed with whole-transcriptomic
and genome-widemethylation data that the effect of our ap-
proach is specific for the target gene of interest, CDKL5.
MATERIALS AND METHODS
Cloning of sgRNAs
For the cloning of CDKL5 sgRNAs 20-bp spacer se-
quences were selected within ±1 kb of the CDKL5 TSS
(chrX:18 443 725, hg19) using the online tool CHOPCHOP
(32). For transient transfection experiments, sgRNAs were
cloned into a sgRNAexpression vector (Addgene plasmid#
73797) following a previously published protocol (33). For
transductions, sgRNAs were cloned into a lentiviral expres-
sion vector (Addgene plasmid # 73797) as previously de-
scribed (34). Spacer sequences used to create target-specific
sgRNA expression vectors are listed in Supplementary Ta-
ble S1. All constructs were sequence confirmed by Sanger
sequencing (Genewiz, Inc, South Plainfield, NJ, USA) and
chromatograms were analysed using SnapGene software
(from GSL Biotech; available at snapgene.com).
Transient transfection experiments
U87MG (ATCC, Manassas, VA, USA) and Lenti-X 293T
(Takara Bio USA, Inc., Mountain View, CA, USA) were
grown in media containing high-glucose DMEM supple-
mented with 1% L-glutamine (Thermo Fisher Scientific,
Waltham, MA, USA) and 10% HyClone heat-inactivated
FBS (Thermo Fisher Scientific). BE(2)C (ATCC) cells were
grown in DME/F12 (Thermo Fisher Scientific) supple-
mented with 1% L-glutamine and 10% HyClone heat-
inactivated FBS. For gene expression modulation exper-
iments, cells per well were grown to 80% confluency
and transfected within 24 h of plating using Lipofec-
tamine 3000 (Life Technologies) following the manu-
facturer’s instructions with 3 ul of Lipofectamine 3000
reagent diluted in 500 ul Opti-MEM reduced serum me-
dia (Thermo Fisher Scientific). Transfections were per-
formed in 12-well plates using either a mock-treatment
(diluted transfection reagent) or 700 ng dCas9 expres-
sion vector (Fuw-dCas9-Tet1CD-P2A-BFP, Addgene plas-
mid #108245; Fuw-dCas9-Tet1CD IM, Addgene plasmid
# 84479; pLV hUbC-dCas9-T2A-GFP, Addgene plasmid #
53191; pLV hUbC-dCas9 VP64-T2A-GFP, Addgene plas-
mid # 53192) and 300 ng of equimolar pooled sgRNA
expression vectors. Transfection medium was replaced 24
h post-transfection with complete growth medium. Forty-
eight hours post-transfection, cells were rinsed in 1XDPBS
(Thermo) and lysed in the well using TriZol (Ambion,
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Austin, TX, USA). Total RNA was extracted using the
Direct-zol RNA Miniprep kit (Zymo Research, Irvine,
CA, USA) and 500 ng RNA was reverse transcribed us-
ing RevertAid First Strand cDNA Synthesis Kit accord-
ing to the manufacturer’s instructions using random hex-
amer primers. Real-time PCR was performed in triplicate
with 20 ng of cDNA per reaction and PowerUp SYBR
Green Master Mix (Thermo Fisher Scientific) using the
StepOne Plus Real Time PCR system (Thermo Fisher Sci-
entific) and the StepOne Plus software was used to ex-
tract raw CT values. Gene expression analysis was per-
formed with GAPDH as a reference gene in three bio-
logical replicates using exon-spanning primers for CDKL5
and GAPDH. All primer oligonucleotides used in this
study are listed in Supplementary Table S1. Fold change of
gene expression was calculated as the delta delta CT be-
tween GAPDH and CDKL5 transcript levels normalized
to mock-treated relative CDKL5 transcript levels as the
reference.
Integrative XCI status analysis of CDKL5
In order to determine the XCI status of CDKL5, we used
publicly available data from GTEx (https://gtexportal.org)
to determine the sex-biased expression using 27 GTEx v6p
tissues and blood dendritic cells from a female of Asian an-
cestry (24A) to assess XCI status of CDKL5 (16). We used
publicly available microarray data to identify a single nu-
cleotide polymorphism (SNP) in the CDKL5 gene of SH-
SHY5Y (35). We isolated genomic DNA from SH-SY5Y
using the Quick-gDNAMiniPrep kit (ZymoResearch). To-
tal RNAwas extracted using the Direct-zol RNAMiniprep
kit (Zymo Research) and 500 ng RNA was reverse tran-
scribed using RevertAid First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific). We confirmed the presence of
the coding SNPs rs34567810 in CDKL5 and rs1808 in the
escape gene CA5B via Sanger sequencing (Genewiz, Inc) of
both genomic DNA and RNA. Chromatograms were ana-
lyzed using SnapGene software (GSL Biotech).
Lentivirus production and purification
To produce lentiviral particles as described before (36), a to-
tal of 50 million Lenti-X 293T cells were seeded into two
T-225 flasks per viral packaging the day before transfec-
tion in high glucose DMEM supplemented with 10% fe-
tal bovine serum and 1% L-glutamine. For each flask 25 g
of dCas9, dCas9-VP64, dCas9-TET1CD or sgRNA expres-
sion vector, 5 g of pMD2.G (envelope, Addgene plasmid
# 12259), and 25 g of psPAX2 (gag/pol, Addgene plas-
mid #12260) were complexed with 140 ul using TransIT-
293 (Mirus,Madison,WI, USA) according to the manufac-
turer’s recommendation in Opti-MEM. Forty-eight hours
after transfection, media was changed to 15mL of Ultra-
CULTURE medium (Lonza, Basel, Switzerland). Vector
supernatants were collected 72 hours post-transfection. Su-
pernatant is initially centrifuged at 1500 rpm to clarify me-
dia and then concentrated by centrifugation at 3000 rpm us-
ing Centricon-Plus-70-Centrifugal-Filter-Units (MilliPore-
Sigma, Burlington, MA, USA). Viral aliquots were stored
at –80◦C. Virus for the expression of dCas9 effectors was
titered by transduction of Lenti-X 293T cells and analyzed
by flow cytometry for expression of GFP and BFP. All flow
cytometry analyses were performed on the BD Fortessa at
the UC Davis Flow Cytometry Shared Resource Core. Vi-
ral titers for the expression of sgRNAs were determined
by using the qPCR lentivirus titration kit (Applied Biologi-
calMaterials Inc., Richmond, BC). SH-SY5Y (ATCC) cells
were grown in DME/F12 media containing 20% FBS and
1% L-glut. SH-SY5Y cells were seeded on six-well plates
at a density of 300 000 cells per well and co-transduced
with equimolar levels of dCas9 lentiviral particles equiva-
lent to one Lenti-X 293T and a volume of dCas9 lentivirus
equivalent to one Lenti-X 293T transducing unit and 5 ×
107 IU of each sgRNA expression vector in combination
with 2.5 g/ml protamine sulfate (Fresenius Kabi, Lake
Zurick, IL). For cells co-transduced with dCas9-VP64 and
dCas9-TET1CD lentiviral volumes equivalent to 0.5 Lenti-
X 293T transducing units each were used. Cells were sorted
5 days post-transduction at passage 11 for expression of
GFP and/or BFP using the Influx cell sorter at the UC
Davis FlowCytometry SharedResource Core (Sacramento,
CA, USA) and further expanded for 3–4 passages for sub-
sequent analysis.
Targeted X-reactivation analysis
SH-SY5Y cells from each FACS-isolated treatment group
and unsorted cells were seeded at a density of 300 000 cells
per well in six-well plates and allowed to grow until ∼70%
confluency. Cells were then rinsed in 1× DPBS and lysed in
the well using TriZol (Ambion). Total RNA was extracted
using the Direct-zol RNA Miniprep kit (Zymo Research)
and 500 ng RNA was reverse transcribed using RevertAid
First Strand cDNA Synthesis Kit (Thermo Fisher Scien-
tific). For X-reactivation analysis, 100 ng of cDNA from
stable SH-SY5Y lines was used for PCR amplification us-
ing Phusion High Fidelity Mastermix (New England Bio-
labs, Ipswich, MA, USA). Each forward primer contained
a unique 5-bp barcode sequence at the 5′ end for multiplex-
ing (Supplementary Table S1). All amplicons were gel ex-
tracted and purified using the Zymo Gel DNA Recovery
kit (ZymoResearch) and pooled at equal concentrations for
Illumina sequencing. Amplicon sequencing was performed
by the CCIB DNA Core Facility at Massachusetts Gen-
eral Hospital (Cambridge,MA,USA). Forward and reverse
reads of raw sequencing data were merged into a single long
read using FLASH2 and barcodes were demultiplexed us-
ing FASTX at the beginning or end of the sequence read,
allowing for a single mismatch each, yielding a mean read
depth of >10 000 reads per sample. Processed FASTQ files
were then analyzed for frequency of reads containing the re-
activated C allele for the coding SNP rs35478150 identified
in exon 16 of the CDKL5 gene with the grep function over
the total number of matched reads, yielding the reactiva-
tion frequency. Allele-specific RT-qPCR was performed as
described above using a common forward primer and allele-
specific reverse primers for the same coding SNP as ana-
lyzed by amplicon sequencing (Supplementary Table S1).
Reactivation percentage was calculated as the percentage of
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relative Xi CDKL5 expression over relative Xa CDKL5 ex-
pression from mock-treated cells, normalized to GAPDH.
Targeted DNA demethylation analysis
Genomic DNA from transduced and mock-treated cells
was isolated using the Quick-gDNA MiniPrep kit (Zymo
Research). Bisulfite conversion was performed using the
EZ DNA Methylation-Gold Kit (Zymo Research) follow-
ing the manufacturer’s instructions. Primers for bisulfite-
sequencing PCR were designed using MethPrimer with
default settings (37) and unique 5-bp barcode sequences
were added at the 5′ end for multiplexing (Supplemen-
tary Table S1). 100 ng of bisulfite converted DNA was
used for PCR amplification with ZymoTaq polymerase
(Zymo Research) and the 238-bp amplicon was purified
with the QIAquick PCR Purification Kit (Qiagen, Hilden,
Germany) and submitted for amplicon sequencing. Ampli-
con sequencing was performed by the CCIB DNA Core
Facility at Massachusetts General Hospital (Cambridge,
MA) and further processed as described above. Align-
ment of processed FASTQ files and read mapping to a
238 bp reference amplicon was performed using Bismark
with default settings (38). Further analysis and methy-
lation calling of sorted BAM files was performed using
CGMapTools (39).
Chromatin immunoprecipitation (ChIP) and ChIP-qPCR
ChIP was performed as previously described (40). Mock-
treated and transduced cells were cross-linked 3–4 passages
after FACS as described above in 1% formaldehyde for 10
min at room temperature and the reaction was stopped with
0.125M glycine. Cross-linked cells were lysed with ChIP ly-
sis buffer (5 mM PIPES pH 8, 85 mMKCl, 1% Igepal) with
a protease inhibitor (PI) cocktail (Roche). Nuclei were col-
lected by centrifugation at 2000 rpm for 5 min at 4◦C and
lysed in nuclei lysis buffer (50mMTris pH 8, 10mMEDTA,
1% SDS) supplemented with PI cocktail. Chromatin was
fragmented using the Bioruptor Pico (Diagenode, Denville,
NJ, USA) and diluted with 5 volumes RIPA buffer (50 mM
Tris pH 7.6, 150 mM NaCl, 1 mM EDTA pH8, 1% Igepal,
0.25% deoxycholic acid). ChIP enrichment was performed
by incubation with 3 g H3K27me3 antibody (ab6002, Ab-
cam, Cambridge, UK) or 2g normal rabbit IgG (ab46540,
Abcam) for 16 h at 4◦C. Immune complexes were bound to
20 l magnetic protein A/G beads (Biorad, Hercules, CA,
USA) for 2 h at 4◦C. Beads were washed 2× with RIPA
(Thermo Fisher Scientific) and 3 × with ChIP wash buffer
(100 mM Tris pH 8, 500 mM LiCl, 1% deoxycholic acid).
The final wash was performed in ChIP wash buffer with 150
mMNaCl. Cross-links were then reversed by heating beads
in 100 l ChIP elution buffer (50 mM NaHCO3, 1% SDS)
overnight at 65◦C, and DNA was purified using the QI-
Aquick PCR Purification Kit (Qiagen, Hilden, Germany).
ChIP-qPCR was performed with PowerUp SYBR Green
Master Mix (Thermo Fisher Scientific) using the StepOne
Plus Real Time PCR system (Thermo Fisher Scientific) and
the StepOne Plus software was used to extract raw CT val-
ues. ChIP enrichment was calculated relative to input sam-
ples using the delta CT method.
Whole-genome methylation analysis by Infinium Methyla-
tionEPIC array
Whole genome methylation analysis was performed follow-
ing (40). Briefly, 300 000 cells for each treatment group were
seeded in 6-well plates and allowed to grow to ∼70% con-
fluency. Genomic DNA from transduced and mock-treated
cells in biological duplicates was isolated using the Quick-
gDNA MiniPrep kit (Zymo Research) and 500 ng submit-
ted for bisulfite conversion and Illumina’s Infinium Methy-
lationEPIC BeadChip array by the Vincent J. Coates Ge-
nomics Sequencing Laboratory (Berkeley, CA, USA). The
minfi package (41,42) was used to extract two channel raw
data (RGChannelSet) from the IDAT files at the probe
level for all 850,000 probes. The RGChannelSet was used
for background subtraction using preprocessNoob (43) fol-
lowed by preprocessFunnorm (44) to normalize the sam-
ples. Beta values for each site (beta = M/(M+U), where
M and U denote the methylated and unmethylated signals)
were extracted from theGenomicRatioSet, which is the data
organized by the CpG locus level mapped to the genome.
The ChAMP package (45) was used to filter probes using
default settings with filterXY set to false. We then used the
limma function within ChAMP (46,47) to detect differen-
tially methylated positions at default settings and merged
the output file with the individual FunNorm beta values. In
order to determine differentially methylated promoter re-
gions, CpG sites were selected for cgi.feat. TSS200-island
and TSS1500-island and a mean difference in beta value
of ±0.05. Differentially methylated genes were defined as
genes with at least 3 differentially methylated positions in
the promoter. Venn diagrams were generated using http:
//bioinformatics.psb.ugent.be/.
RNA-Seq library preparation and analysis
Global changes to transcription were assessed using
RNA-Seq. Briefly, 300 000 cells for each treatment group
were seeded in six-well plates and allowed to grow to
∼70% confluency. Cells were then rinsed in 1× DPBS and
lysed in the well using TriZol (Ambion). Total RNA was
extracted using the Direct-zol RNA Miniprep kit (Zymo
Research). RNA was quantified with Nanodrop and 1 ug
of RNA was used for each library. RNA libraries were
generated using the NEBNext Ultra II RNA Library Prep
kit (NEB) following manufacturer’s instructions. Libraries
were multiplexed and pooled for a single lane of sequencing
on a HiSeq4000. Sequencing reads were de-multiplexed
and aligned to the Hg38 reference genome with STARUni-
versal Aligner version 2.5.3a using the following settings:
Indexed Reference Genome: Ensembl reference genome and
annotation files for Hg38 release 77 were downloaded and
complied into a single file, Genome was indexed using the
following arguments ‘STAR –runMode genomeGenerate
–runThreadN 12 –genomeDir /STAR INDEX HG38
–genomeFastaFiles GRCh38 r77.all.fa –sjdbGTFfile
Homo sapiens.GRCh38.77.gtf –sjdbOverhang 149’; Sam-
ple Read Alignment: alignment of each sample’s reads
was performed with the following arguments: ‘STAR
–runThreadN 24 –genomeDir /STAR INDEX HG38 –
outFileNamePrefix /STAR/SampleName –outSAMtype
BAM SortedByCoordinate –outWigType bedGraph
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–quantMode TranscriptomeSAM GeneCounts –
readFilesCommand zcat –readFilesIn Sample-R1.fastq.gz
Sample-R2.fastq.gz’. Differential Expression (DE) analysis
was performed with DESeq2 (48) software in R Studio.
First, gene count files were combined into a single file.
Then, normalization and DE analysis were performed
using a dCas9 control. DE gene lists from pairwise com-
parisons were exported into .csv files and utilized for GO
term analysis using DAVID (https://david.ncifcrf.gov).
Volcano plots were generated using ggplot2 software in R
studio.
Off-target analysis
Off-target analysis of CRISPR sgRNAs was performed
using the CasOFFinder tool (http://www.rgenome.net/cas-
offinder/) (49). Briefly, 20bp spacer sequences for the three
top sgRNA candidates without PAM sequences were used
as the query using hg38 as the reference genome for canon-
ical SpCas9 PAM sites. The algorithm was executed using
three or less mismatches and DNA and RNA bulge sizes of
1. In order to extend the list from off-target sites to poten-
tial off-target genes, we included genes in a ±5 kb window
using the Table Browser function of the UCSC Genome
Browser. The list of off-target genes was then overlapped
with all differentially expressed genes from the three con-
ditions as well as differentially methylated probes from the
dCas9-TET1CD comparison with dCas9 catalytically inac-
tive TET1.
Statistical analysis
Statistical analyses were performed in Prism 8 (GraphPad
Software, San Diego, CA, USA) and in R Studio 3.6.0.
Statistics are presented as the mean ± SD. Targeted assess-
ments were performed in biological triplicates. Genome-
wide assessment were performed in triplicates unless other-
wise noted. Between-group differences were analyzed using
a One-way analysis of variance (ANOVA). When appropri-
ate, a Tukey’s post hoc test was performed. Statistical differ-
ences between themeans of two groups were determined us-
ing an independent samples t test. TheP value cut-off for all
targeted analyses was set at 0.05 for all analyses. Statistical
analyses of differentially methylated sites were performed
using the limma function embedded in ChAMP in R Studio
3.6.0. The null hypothesis was rejected for tests with FDR
<5%. Statistical analyses of differentially expressed genes
was performed using DESeq2 in R Studio 3.6.0. The null
hypothesis was rejected for tests with FDR <1%.
RESULTS
Programmable transcription of the CDKL5 gene
In order to investigate if the CDKL5 gene is amenable
for transcriptional reprogramming via dCas9 effector do-
mains we transiently co-transfected U87MG cells with
dCas9 constructs and gRNA expression vectors. We used a
dCas9-VP64 expression plasmid (dC-V). Plasmid express-
ing dCas9 without effector domain was used as a control
(dC). We designed six individual guide RNAs spanning
DNase I hypersensitive sites and H3K4me3 peaks of the
CDKL5 promoter within a ±1 kb window on either side
of the CDKL5 transcriptional start site (Figure 1A). On
the basis of previous observations that several guide RNAs
are required for gene activation with dC-V (50), we tested
several combinations of 3–6 guide RNAs (Figure 1B). We
performed RT-qPCR and observed significant activation of
CDKL5 expression with the combination of guide RNAs
1–3 paired with dC-V targeting a region upstream of the
transcriptional start site. CDKL5 expression increased 1.6-
fold in U87MG cells when compared to dC (P= 0.023). No
significant difference between dC and dC-V was observed
with cells transfected with guide RNAs 1–6 or guide RNAs
4–6. In concordance with U87MG cells, transfection with
guideRNAs 1–3 and dC-V revealed a 1.3-fold and a 1.6-fold
upregulation of CDKL5 in BE2C cells (P = 0.0112, Figure
1C) and in HEK293 (P = 0.0424, Figure 1D), respectively,
when compared to cells transfected with dC. Therefore, our
results demonstrate the identification of a cis-regulatory ele-
ment in theCDKL5 promoter that allows for programmable
transcription.
dCas9-TET1CD significantly reactivates silenced CDKL5
expression
Due to the lack of informative allele-specific polymor-
phisms in either of the previously tested cell lines we ex-
amined bi-allelic mRNA activation in female SH-SY5Y
cells in order to assess whether the increase in gene expres-
sion was due to superactivation of the active CDKL5 al-
lele, reactivation of the silenced allele, or a combination
of both. Data from a previously published comparative
analysis across several GTEx tissues (16) demonstrate that
CDKL5 does not display female-biased expression, which
serves as a proxy for XCI status when compared to the
known escape gene CA5B (Supplementary Figure S1A).
Analysis of XCI using pre-existing scRNA-seq data (16) to
assess allele-specific expression from lymphoblastoid cells
further revealed that CDKL5 is monoallelically expressed
only from the active X chromosome (Supplementary Fig-
ure S1B). In order to distinguish between the active and the
inactive CDKL5 allele, we confirmed the presence of a SNP
(rs35478150) in the coding region of the CDKL5 gene in
SH-SY5Y cells. Sanger sequencing confirmed monoallelic
expression of the active CDKL5 A allele and silencing of
the C allele. We also examined expression of a polymorphic
site in CA5B, which showed bi-allelic expression from the
active and escape allele (Supplementary Figure S1C).
Due to the importance of methylated CGI promoters in
XCI, we investigated the role of a dCas9-TET1CD fusion
protein for DNA methylation editing (dC-T). In order to
determine X chromosome reactivation efficiency, we evalu-
ated allele-specific activation facilitated by dC-V or dC-T.
SH-SY5Y cells were transduced with lentiviral particles en-
coding the dC fusion proteins and the three guide RNAs.
dCas9 expression plasmids also encode in-frame fluores-
cent markers GFP (dC and dC-V) or BFP (dC-T). Three
days following transduction, transduced cells were selected
by FACS based on the respective fluorescent marker (Sup-
plementary Figure S2A).
To determine reactivation of the silenced CDKL5 allele
with high sensitivity, we performed amplicon-based tar-
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Figure 1. Programmable transcription of the CDKL5 gene. (A) UCSC genome browser snapshot of the target sites of the six sgRNAs directed against the
CDKL5 promoter on Xp22.13. DNase hypersensitive sites and H3K4me3, often found near promoters are derived from ENCODE. Sense sgRNAs are
shown in blue, antisense sgRNAs in red. (B) CDKL5mRNA fold change relative to mock-treated cells in U87MG cells determined by RT-qPCR resulting
from programmable transcription using a dCas9-no effector (dC) or dCas9-VP64 (dC-V) in combination with different pools of three to six sgRNAs
targeted to the CDKL5 promoter 48 h after transient transfection. #Significantly different from dCas9 sgRNAs 1–3, n = 3 independent experiments,
Tukey’s HSD, P < 0.05. (C) CDKL5 mRNA fold change relative to mock-treated cells in BE2C determined by RT-qPCR resulting from programmable
transcription using dCas9-no effector or dCas9-VP64 co-expressed with sgRNAs 1–3 48 h after transient transfection. (D) CDKL5 mRNA fold change
relative to mock-treated cells in Lenti-X 293T determined by RT-qPCR resulting from programmable transcription using dCas9-no effector or dCas9-
VP64 co-expressed with sgRNAs 1–3 48 h after transient transfection. #Significantly different from dCas9 sgRNAs 1–3, n = 3 independent experiments,
Student’s t-test P <0.05.
geted RNA-sequencing (Figure 2A). Targeting of dC to
CDKL5 was sufficient to significantly reactivate expression
of the silenced allele by>11-fold to 8% of total allelic reads
compared to mock-treated cells (P < 0.0001). Transcrip-
tional reprogramming using dC-V targeted to the CDKL5
promoter did not show a significant increase when com-
pared to dC. Strikingly, cells transduced with dC-T showed
a 20.7-fold increase when compared to mock (P<0.0001)
and a significant 1.8-fold increase above dC (P < 0.0001),
leading to reactivation levels of up to 14.5% of total expres-
sion. Since dC-V has been shown to increase total CDKL5
mRNA in other cell lines tested, we sought to determine if
multiplexing dCas9-VP64 and dCas9-TET1CD (dC-T+dC-
V) to the same locus further potentiates CDKL5 reactiva-
tion. However, no significant difference was observed be-
tween dC-T and co-transduction of dC-T+dC-V in increas-
ing the proportion of allelic reads derived from the inactive
allele.
Due to the fact that the observed allelic reads via ampli-
con sequencing are a ratio of active versus silenced CDKL5
expression, we performed allele-specific RT-qPCR in order
to compare reactivation levels from the inactive allele to
the active allele baseline expression in SH-SY5Y (Figure
2B). Similar to our amplicon sequencing data, we did not
identify expression of the inactive allele above background
(<1% Xi/Xa mock). We observed expression levels in cells
transduced with dC of 14.8% Xi/Xa mock in cells treated
with dC. No statistically significant increase in Xi/Xamock
expression over dC was observed in cells treated with dC-
V (27.3%) or dC-T (38.2%). However, SH-SY5Y cells that
were co-transduced with dC-V+dC-T showed a statistically
significant increase of reactivation from the inactive allele
(67.4%) when compared to dC (P = 0.0004), dC-V (P =
0.042) and dC-T (P = 0.038). These findings suggest that
SH-SY5Y that have been treated with the dCas9 effector
domains reach close to equal bi-allelic expression due to a
synergistic effect of dC-V and dC-T on the previously silent,
reactivated allele.
For the expression of the active CDKL5 allele, we ob-
served no significant difference between dC and mock-
treated cells (Figure 2C). Moreover, we identified that dC-V
significantly upregulates mRNA expression from the active
allele by 3.0-fold when compared to mock (P = 0.0052) or
2.7-fold when compared to dC (P= 0.0073). No significant
difference was observed between mock cells versus dC-T or
dC-V+dC-T and dC versus dC-T or dC-V+dC-T. Notice-
ably, targeting dC-T to the CDKL5 promoter did not sig-
nificantly modulate active CDKL5 mRNA levels.
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Figure 2. Targeted reactivation of CDKL5 from the inactive X allele. (A) Allele specific read counts for the mRNA expression of the active (Xa) or inactive
(Xi)CDKL5 allele ofmock-treated SH-SY5Yor after constitutive expression of dCas9 effector domains dCas9 (dC), dCas9-VP64 (dC-V), dCas9-TET1CD
(dC-T) or a combination of dCas9-VP64 and dCas9-TET1CD (dC-V+dC-T) and sgRNAs 1–3 after 21 days post-transduction. #Significantly different
frommock-treated, ‡significantly different from dCas9, n= 3 independent experiments, Tukey’s HSD,P< 0.05. (B) Relative XiCDKL5mRNA expression
of mock-treated or stably transduced SH-SY5Y relative to CDKL5 Xa mRNA expression of mock-treated cells as determined by allele-specific RT-qPCR
after 21 days post-transduction. #Significantly different from dC, ‡significantly different from dC-V, †significantly different from dC-T, n = 3 independent
experiments, Tukey’s HSD, P < 0.05 (C) Relative Xa CDKL5 mRNA expression in mock-treated and stably transduced SH-SY5Y cells determined by
allele-specific RT-qPCR after 21 days post-transduction. #Significantly different frommock-treated, ‡significantly different from dCas9, n= 3 independent
experiments, Tukey’s HSD, all P < 0.05.
dCT significantly reduces DNA methylation
The status of XCI is highly correlated to promoter CGI
methylation (12,20). Due to the differences in targeted re-
activation between effector domains, we performed targeted
bisulfite amplicon sequencing in theCDKL5 core promoter
region in order to identify the role of differential DNA
methylation in X-reactivation between groups (Figure 3A).
We generated PCR-based amplicons that allowed us to
measure the ratio of 5-meCG/total CG at 24 CpG individ-
ual dinucleotides in the CDKL5 core promoter by deep se-
quencing (Figure 3B, Supplementary Figure S3). Due to the
lack of a polymorphism in the promoter region, we assessed
biallelic CpG methylation, assuming that DNA methyla-
tion was primarily present on the XCI silenced allele. We
observed two segments of DNA methylation that were de-
marcated by a dip in methylation at CpG dinucleotide posi-
tion 12. The first segment showed that theCDKL5 promoter
was partiallymethylated inmock-treated SH-SY5Y (53% 5-
meCG/CG ± 0.9%, Figure 3B), while the second segment
showed a decreased baseline DNA methylation level and
more variability of 5-meCG/CG (25.4% 5-meCG/CG ±
16.8%, Supplementary Figure S3), suggesting that partial
methylation of the core region containing the first 11 CpGs
is critical for regulation ofCDKL5 transcription. Amplicon
sequencing of bisulfite converted genomic DNA revealed
the mean 5-meCG/total CG ratio across the first 11 CpG
sites was 53.3% in mock and 51.6% in dC transduced cells
(Figure 3C). Strikingly, we observed a 17.5% decrease of
5-meCG/CG in cells transduced with dC-T compared to
mock-treated cells (P < 0.0001) and a 15.9% decrease to
dC (P<0.0001).We demonstrate that this heterogeneous re-
sponse on the bulk level is due to the catalytic activity of dC-
T, since a catalytically inactive TET1 mutant (dC-dT) fails
to disrupt methylation at 51% 5-meCG/CG (P < 0.0001).
The combinatorial treatment of dC-T+dC-V also showed
a significant reduction in methylation levels of 14.3% com-
pared to mock-treated cells (P < 0.0001) and 12.6% com-
pared to dC (P < 0.0001). However, the combination of
dC-T and dC-V had significantly higher levels of methyla-
tion when compared to dC-T alone. Interestingly, the com-
bination of dC-T and dC-V had the greatest increase of the
inactive allele. This may be due to TET1 achieving a level
of demethylation that allows for gene transcription. In fact,
the addition of dC-V significantly decreased the amount of
demethylation, indicating, that dC-V does not contribute to
DNA demethylation as a mechanism of transcriptional ac-
tivation.
Targeted loss of repressive H3K27me3 in the CDKL5 pro-
moter
As previously demonstrated, genes that escape from XCI
show a specific epigenetic signature, such as the depletion
of the repressive histone mark H3K27me3. Therefore, we
sought to investigate whether targeted reactivation of the
observed allele coincided with a remodelling of heterochro-
matin. We used ChIP-qPCR to test three different regions
within a 1-kb fragment upstream of the transcriptional start
site for changes in theH3K27me3mark that have strong sig-
nal enrichment in brain tissue as determined by ENCODE
and overlap the guide RNA target sites (Figure 4A). When
compared to mock-treated cells, treatment with dC by it-
self depleted H3K27me3 signal 3.5-fold in region A (P =
0.0073, Figure 4B); 2.9-fold in region B (P = 0.0002, Fig-
ure 4C) and 1.5-fold in region C (P = 0.00453, Figure 4D).
There was no significant difference between treatment with
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Figure 3. dCas9-TET1CD causes removal of DNA methylation from the CDKL5 CGI promoter. (A) UCSC genome browser snapshot of the target sites
of sgRNAs 1–3 directed against the CDKL5 promoter on Xp22.13 and a large CpG Island (>1 kb) spanning the transcriptional start site of CDKL5.
The black box represents a >200 bp region assessed for targeted DNA methylation changes containing 24 individual CpG dinucleotides (drawn to scale).
(B) 5-methylcytosine levels in a CpG context (5meCG) over total CpG context as assessed by targeted bisulfite sequencing across 11 CpG dinucleotides
in mock-treated cells or cells transduced to constitutively express dCas9-no effector (dC) or dCas9 fused to either VP64 (dC-V) or TET1CD (dC-T),
a combination thereof (dC-V+dC-T) or a catalytically inactive TET1CD (dC-dT). X-axis depicts the individual CpG position relative to the amplicon
(not drawn to scale). (C) Mean 5-methylcytosine levels in a CpG context over all 11 CpG dinucleotides in all treatment groups. #Significantly different
from mock-treated cells, ‡significantly different from dCas9, †significantly different from dC-dT, significantly different from dC-T, n = 3 independent
experiments, Tukey’s HSD, all P < 0.05.
dC, dC-V or dC-T. In order to understand the effect of
histone-based feedback and spreading of the depletion of
the histone mark across neighboring nucleosomes in our
treated cells, we investigated the signal of H3K27me3 in
distal neighboring regulatory regions. We performed ChIP-
qPCR on the nearest neighboring gene to the CDKL5 pro-
moter (–70 kb) and tested for H3K27me3 signal (Figure
4E). There were no significant differences between groups
forH3K27me3 signal in the promoter region of the SCML2
gene. Therefore, it is suggestive that the loss of H3K27me3
remains confined to the target site and is associated with
gene reactivation. Finally, no significant difference between
groups was observed for H3K27me3 signal at an unrelated
negative control region in theMECP2 promoter on the long
arm of the X chromosome (Figure 4F).
dC-T transduced cells show global promoter hypomethylation
In order to determine on- and off-target effects of dC-T on
the DNA methylome in stably transduced SH-SY5Y cells,
we used the Illumina Infinium HumanMethylationEPIC
(EPIC) array to interrogate 764 090 CpG sites genome-
wide (Supplementary Table S2, Figure S4). We identified a
smaller subset of 147 870 probes (19.4%) within CpG is-
lands. Out of this subset, we further enriched for 59 264
probes that were found within 1500 and 200 bp of the TSS.
Understanding the role of dCas9 binding to distal regula-
tory elements was outside of the scope of the analysis. In our
pairwise comparisons to determine differentially methy-
lated (DM) positions between dC-T and dC-dT or dC, we
set a cut-off of mean difference in beta value greater than
0.05 (FDR < 5%). In order to validate our criteria, we first
analyzed all 32 methyl-probes mapping to the CDKL5 gene
without filtering for probe features (Figure 5A and B). In
concordance with our targeted bisulfite approach, we iden-
tified partial methylation of the promoter region of control
treated cells (dC, dC-dT), which was modestly but signifi-
cantly reduced near the sgRNA target site (Figure 5A, red
line) in cells transduced with dC-T. We did not identify DM
positions in any of the other genic features, which further
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Figure 4. Depletion of the XCI hallmark histone modification H3K27me3. (A) UCSC genome browser snapshot of the target sites of sgRNAs 1–3 directed
against the CDKL5 promoter on Xp22.13 and H3K27me3 peaks derived from ENCODE. Black boxes show the regions assessed by ChIP-qPCR. (B)
Input normalized H3K27me enrichment levels determined by ChIP-qPCR in region A of the CDKL5 promoter in mock-treated cells or cells transduced
to constitutively express dCas9-no effector (dC) or dCas9 fused to either VP64 (dC-V) or TET1CD (dC-T). (C) Input normalized H3K27me enrichment
levels determined by ChIP-qPCR in region B of the CDKL5 promoter. (D) Input normalized H3K27me enrichment levels determined by ChIP-qPCR in
regionC of theCDKL5 promoter. (E) Input normalizedH3K27me enrichment levels determined byChIP-qPCR in the promoter of the nearest neighboring
gene promoter, SCML2. (F) Input normalized H3K27me enrichment levels determined by ChIP-qPCR in the promoter of a distal gene, MECP2, that
serves as a negative control. #Significantly different from mock-treated cells, n = 3 independent experiments, P < 0.05.
demonstrates the highly distinctive role of DNA methyla-
tion signatures in CGI promoters. No DM positions were
identified in the nearest neighboring gene to the CDKL5
promoter (SCML2) once again confirming that the dC-T-
inducedDNAdemethylation is targeted to theCDKL5 pro-
moter. In total, we identified 795 or 747 differentially hy-
pomethylated promoters and 34 or 26 differentially hyper-
methylated promoters for the comparison between dC-T
and dC or dC-dT, respectively. Due to the small number of
differentially hypermethylated sites and the fact that gene
repression due to off-target hypermethylation of TET1CD
is unlikely, we omitted hypermethylated sites from the fur-
ther analysis. The majority of differentially hypomethylated
sites in gene promoters due to the introduction of dC-T
showed only a single DM position (568 genes when com-
pared to dC, 402 geneswhen compared to dC-dT), likely not
eliciting an effect on transcription (51) (Figure 5C). Since
CDKL5 had at least 3 differentially hypomethylated sites,
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Figure 5. Global DNA hypomethylation due to constitutive dCas9-TET1CD expression. (A) Thirty-two CpG positions shown with their respective
location on the X-chromosome (hg19) from the 850KMethylationEPIC array across theCDKL5 promoter were used to assess gene-wide changes in DNA
methylation levels represented as changes in the beta value of the TSS200, TSS1500, 5′UTR and gene body of CDKL5. After transduction with dCas9-no
effector (dC), dCas9-TET1CD (dC-T) and a catalytically inactive TET1CD (dC-dT), we found reducedDNAmethylation levels in the TSS1500 andTSS200
region of cells transduced with dCas9-TET1CD. The red line demonstrates the sgRNA binding sites in the CDKL5 promoter. *Significantly differentially
methylated positions for further assessment. (B) Side-by-side assessment of significantly differentially methylated positions in the CDKL5 promoter with a
mean difference in beta value of <0.05. #Significantly different from dC, †significantly different from dC-dT, n = 2 independent experiments, FDR < 5%.
(C) Histogram of the number of genes by the number of significantly hypomethylated sites of dCas9-TET1CD transduced cells when compared to dCas9
or a catalytically inactive TET1 fused to dCas9 demonstrates that the majority of genes shows only a single probe falling within the respective promoter
region. (D) Side-by-side assessment of significantly differentially methylated positions in the COL9A3 promoter with a mean difference in beta value of
<0.05. #Significantly different from dC, †significantly different from dC-dT, n= 2 independent experiments, FDR< 5%. (E) Venn diagram of shared genes
between dCas9-TET1CD comparisons with dCas9 or a catalytically inactive TET1CD mutant shows an overlap of 48 genes between the two groups. (F)
A flow chart diagram representing the analysis pipeline for genome-wide methylation effects of dCas9-TET1CD, starting from a total number of probes,
down to significantly differentially methylated sites and ultimately differentially methylated genes.
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Figure 6. Off-target analysis of CRISPR/dCas9 effectors by RNA-seq. (A) Volcano plot of significance (FDR adjusted P value) versus fold change for
differential DESeq2 expression analysis of mock-treated, dCas9-VP64 (dC-V), dCas9-TET1CD (dC-T) or dCas9-VP64 and dCas9-TET1CD (dC-V+dC-
T) guided by sgRNAs 1–3 to the CDKL5 promoter compared to a dCas9-no effector control (dC). Differentially expressed genes are highlighted in red
(FDR< 1%, log fold change>1), predicted CRISPR off-target sites are highlighted in blue and theCDKL5 target gene is highlighted in green. The number
of downregulated genes is found in the upper left of each panel, the number of upregulated genes is found in the upper right of each panel. (B) Venn diagram
showing the overlap of differentially expressed genes between all conditions and the putative off-target list. A single gene, CNTNAP2 is shared between all
four groups as a putative off-target. (C) Venn diagram showing the overlap between differentially expressed genes and differentially methylated positions
identified in a comparison between dCas9-TET1CD and dCas9 and potential CRISPR off-targets.
we only considered genes with at least three DM sites as a
differentially hypomethylated gene promoter. The gene with
the highest number of DM positions was COL9A3, show-
ing eight hypomethylated sites within the promoter (Figure
5D). We identified a total of 69 or 81 genes when compared
to dC or dC-dT respectively. Forty-eight genes were con-
served between the pairwise comparisons (Figure 5E and
F).
Specificity of CDKL5 sgRNAs and dCas9 effector domains
To evaluate the effect of targetingCDKL5with dCas9 effec-
tor fusions on global gene expression we performed RNA-
seq in stably transduced SH-SY5Y.We observed that the in-
troduction of dC alone causes 208 differentially expressed
(DE) genes when compared to mock-treated cells, likely
due to the introduction of the lentiviral machinery (66 up-
and 142 downregulated genes, Figure 6A, Supplementary
Table S3). Therefore, we performed pairwise comparisons
with dC as the control. When compared to cells trans-
duced with dC, we found that cells transduced with dC-
V or dC-V+dC-T targeted to CDKL5 specifically increase
CDKL5 expression without altering expression of adjacent
transcripts (nearest neighboring gene upstream and down-
stream of CDKL5). No significant upregulation of CDKL5
was detected in cells treated with dCas9-TET1CD.We iden-
tified four genes containing heterozygous SNPs in the cod-
ing region within a ±2 Mb range of the CDKL5 target site
(MAP3K15, RAI2, NHS and BEND2, Supplementary Ta-
ble S3). However, mean read counts for these genes were
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generally unchanged from the mock-treated group, albeit
3 out of 4 genes were lowly or not expressed. Regardless,
since the mean read counts for these gene were not sig-
nificantly altered, it is suggestive that the X-chromosomal
genes were not reactivated. In total, we identified 274 dif-
ferentially expressed (DE) genes in dC-V (100 up- and 174
downregulated genes), 84DE genes in dC-T (n= 29 up- and
n= 55 downregulated) and 43 DE genes in dC-V+dC-T (13
up- and 30 downregulated genes). In general, we observed
a greater number of differentially downregulated genes in
transduced cells, which we do not attribute to off-target
binding of the constructs as both effector domains confer
transcriptional activation to direct targets, not repression.
Although CDKL5 sgRNA sequences were designed to
target a unique site in the human genome, it is possible that
our sgRNAs can tolerate mismatches leading to off-target
binding. In order to address this issue, we searched for po-
tential off-target (OT) sites with up to three mismatches
within the sgRNA sequences using CasOFF-Finder, which
scans for both nucleotide mismatches and bulges in the se-
quence, thereby making it a comprehensive in silico predic-
tion tool for OT analysis (49). In order to include OT sites
that fall within intergenic regions, we extended the targets
by±5 kb from the predicted OT site to include neighboring
transcripts and identified a total of 30 predicted OT genes
(Supplementary Table S3). Strikingly, the majority of OT
sites required at least two mismatches, with sgRNA 2 only
being permissive for OT sites with three mismatches in the
sequence. Out of 30 OT genes, we identified a single tar-
get,CNTNAP2, that was downregulated in dC-V, dC-T and
dC-V+dC-T in all three conditions. While the predicted OT
site for CNTNAP2 falls within an intronic sequence of the
gene, we cannot preclude that the differential expression is a
consequence of off-target binding of the dCas9 effector do-
main. Cells transduced with dC-V showed the highest num-
ber of unique differentially expressed transcripts (n = 223),
followed by dC-T (n = 58) and dC-V+dC-T (n = 10). A to-
tal of 16 differentially expressed genes were shared between
the three conditions (Figure 6B). A gene ontology analy-
sis did not reveal significant enrichment of terms, indicating
that the set of DE genes does not share a common pathway
(Supplementary Table S3).
Next, we sought to assess whether the observed global
changes in DNA methylation in cells transduced with dC-
T were associated with altered transcript levels. We investi-
gated the overlap between all 81 differentially hypomethy-
lated genes in CGI promoter regions with greater than
three DM positions, all 84 DE genes and the predicted 30
OT genes (Figure 6C). Overall, we identified that a single
gene (HHIPL1) showed association between differentially
methylation and expression (Supplementary Figure S5). Fi-
nally, we did not identify genes overlapping the OT genes
and DM positions. This data suggests that the observed
global DNA hypomethylation of promoters poorly corre-
lates with gene expression.
DISCUSSION
A significant number of X-linked genes escape XCI and are
expressed from the inactive X chromosome (16). Whether
or not the epigenetic signature associated with these es-
capees is a cause or merely a consequence of expression
fromotherwise transcriptionally inert X-chromatin remains
to be elucidated (17). Here, we demonstrate for one such
epigenetic barrier in a specific gene context, that removal of
CGImethylation from the promoter of the X-chromosomal
gene CDKL5 by directing a fusion of the catalytic domain
of TET1 to dCas9 results in reactivation of gene expression
in a targeted manner. In addition, employment of a strong
transcriptional activator further increases the degree of es-
cape in a synergistic fashion, resulting in expression levels
in excess of 60% of the inactive allele when compared to the
active allele.
We demonstrate that programmable transcription us-
ing a transactivator achieves a moderate but significant
CDKL5 upregulation when compared to other reported
CRISPRa target sites (52) that was achieved across several
cell lines. However, the effect of the VP64 transactivator
was mainly due to superactivation of the already active al-
lele, demonstrating that the epigenetic landscape of active
X-chromatin presents a chromatin state more permissive
for programmable transcription. Unexpectedly, we identi-
fied that binding of dCas9 with no effector was capable of
reactivating CDKL5 expression from the silent allele. This
may be due to the large dCas9 protein serving as a pioneer
factor when constitutively expressed and targeted to tran-
scriptionally inactive X-chromatin, thereby causing limited
gene reactivation on its own in a gene and chromatin spe-
cific context. In contrast to other studies (53,54), we did
not observe hindrance of dCas9 binding to regions largely
embedded in CpG-dense hypermethylated CGI promoters.
We cannot rule out, however, that binding of a sgRNA out-
side of themethylated region on the inactive X chromosome
is, at least in part, causative for the observed effect. This
limited but significant reactivation was associated with the
loss of the repressive histone mark H3K27me3 in the core
promoter of CDKL5. While the direct role between dCas9
binding and depletion of the histonemark is not well under-
stood, it is possible that binding of dCas9 causes displace-
ment of the nucleosome, resulting in the loss of H3K27me3
and enhanced chromatin accessibility (55,56). In this study
we assessed H3K27me3 due to its role in XCI. However, fu-
ture studies to investigate dCas9 effect on nucleosome re-
arrangement would require the assessment of multiple hi-
stone subunits. In line with previous findings (2), we did
not observe a spread of heterochromatin loss to the near-
est neighboring gene, suggesting a targeted effect of dCas9
binding.
Previous studies suggested that nucleosome occupancy
strongly impedes binding of (d)Cas9 (57,58). However, con-
sidering that our sgRNAdesign takesDNase hypersensitive
sites into account, and considering the finding that the in-
active X-allele is ∼1.2-fold more compact than the active
allele (59), we demonstrate that a promoter of a gene on
the inactive X-chromatin is generally targetable by dCas9.
In addition, the accessibility of CDKL5 can be further at-
tributed to the location of the gene on a chromosomal seg-
ment that is part of a younger evolutionary strata of the X
chromosome (17). Indeed, the majority of facultative and
constitutive escape genes are located on the short arm of
the X chromosome (17). Therefore, the chromosomal loca-
tion ofCDKL5might be favorable to induce an artificial es-
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cape. The fusion of VP64 to dCas9 did not further increase
the observed reactivation, further supporting a steric effect
primarily attributed to the large size of dCas9 that is not
augmented by the addition of a small transactivator. The
indirect recruitment of transcription factors by VP64 did
not result in higher reactivation levels and may be due to
the chromatin microenvironment, specifically the presence
of DNA methylation as an epigenetic barrier that does not
permit abundant transcription via VP64.
Changing the chromatin microenvironment via the intro-
duction of TET1CD resulted in decreased DNA methyla-
tion of∼15% in theCDKL5 core promoter and significantly
reactivated XCI-silenced CDKL5, thereby creating an arti-
ficial escape gene as previously defined at expression lev-
els of at least 10% of the active allele (17). While we did
not directly assess the levels of the 5-hydromethylcytosine
intermediate, we demonstrate that targeted removal of 5-
methylcytosine is mediated by the dioxygenase function of
TET1CD. Likely due to the depletion of 5-methylcytosine
substrate in the promoter of the active allele, recruitment
of TET1CD to this region did not result in superactivation
of the allele on the active X chromosome. Due to a lack of
polymorphisms in theCDKL5 promoter of SH-SY5Y cells,
our model system did not allow us to test for allele specific
changes of the epigenetic signature but was reliant on the
assessment of total changes in DNA methylation in light
of the fact that CGI methylation is highly correlative with
the inactive X allele. Furthermore, a recent genome-wide
assessment revealed global DNA hypomethylation of CGI
promoters following TET1CD overexpression via lentivi-
ral integration (29). However, our genome-wide assessment
of promoter regions did not identify a strong correlation
between reduced methylation of CpG sites and changes in
transcription by RNA-seq. This is likely because the vast
majority of genes identified only contain a single differen-
tially methylated site indicative of one CpG dinucleotide,
and the generally small effect size of the measured changes
of DNA methylation. The change of a single CpG site in a
promoter which typically contains multiple CpG sites likely
would not result in biological significance, thus the lack
of correlation with transcriptional activation. Since CGI
promoters on the inactive X allele frequently show higher
methylation levels than on the active X allele, targeted re-
duction of CpGmethylation is directed to a single allele, un-
like the case for autosomal genes. For example, in an auto-
somal setting, directed epigenetic editing may confer small
changes to methylation levels of both alleles. These small
changes do not necessarily translate to an additive effect
on transcription if neither of the alleles reaches a thresh-
old of biological significance. However, targeting a single
X-chromosomal allele of a gene has the potential to con-
centrate the effects of epigenetic editing that would other-
wise be divided over two alleles, increasing its potential to
pass this arbitrary biological threshold. Thus, a decrease
of DNA methylation on the inactive X chromosome can
have a broader implication for regulation of gene expres-
sion. In future studies, the role of dCas9-TET1CD bind-
ing to putative distal enhancers that may result in differ-
ential methylation or gene expression will be assessed. In
addition, it will be crucial to test whether a more tran-
sient delivery of TET1CD impacts the amount of observed
methylation changes. While it was suggested that the ef-
fects of dCas9-TET1CD are specific (26), we and others
demonstrate global DNA methylome changes (29). Simi-
lar findings have been demonstrated for genome-wide DNA
methylation changes with fusions of the DNAmethyltrans-
ferase DNMT3A to dCas9 (60), likely attributed to the high
substrate abundance of methylated cytosines for constitu-
tively expressed nuclear TET1CD not bound to the target
site. This highlights the need to assess transient exposure of
dCas9-effectors to the CDKL5 promoter in order to reduce
potential off-target effects in future studies.
Due to the strong effect of VP64 on upregulating genes
in an unmethylated chromatin context, we assessed a com-
bination of TET1CD and VP64 targeted to CDKL5 via
dCas9. We found a synergistic effect between removal of
DNA methylation and strong transcriptional activation
that resulted in a greater than 60% expression from the in-
active allele. Since the employment of VP64 alone does not
significantly increase reactivation levels, we believe that the
introduction of dCas9-TET1CD causes a dynamic repro-
gramming in which methyl groups are removed from CpG
dinucleotides, thus allowing for further binding of tran-
scription factors to the inactive chromatin via an indirect
recruitment from VP64. These findings support a synergis-
tic effect between TET1CD and transactivators that have
recently been supported by others (28,29). In future stud-
ies, the effect of improved transcriptional activators, such
as the VP64–p65–Rta tripartite fusion (61) or the use of
the SunTag (62) system will be harnessed to further po-
tentiate the expression of XCI silenced CDKL5 in combi-
nation with TET1CD. Interestingly, following dual expres-
sion of VP64 and TET1CD resulted in the fewest number
of DE genes in RNAseq analysis. In silico analysis provided
a predicted list of potential off-target genes either through
base-pair mismatches or bulges in the gRNA. Only a sin-
gle gene from the predicted off-target list, CNTNAP2, a
gene implicated in autism-spectrum disorders (63), demon-
strated differential expression following genome wide tran-
scriptomics. Novelmethodologies have been proposed to al-
ter the binding specificities of sgRNAs in order to reduce
off-target binding, such as engineering a hairpin secondary
structure onto the sgRNA spacer region (64), and will be
explored in future studies.
Up until recently, technical hurdles have hampered the as-
sessment of the role of epigenetic heterogeneity in biological
systems. One challenge that remains is whether the observed
reactivation levels of CDKL5 are due to a limited or partial
reactivation at the population-wide level or if the observed
effects are specific to a fully reactivated subgroup of cells.
Recent evidence suggests that there are specific populations
of cells that are more responsive to targeted effects, which
will then drive the phenotype at the bulk level (28). It is pos-
sible that there are different kinds of responders to the epi-
genetic edits in our tested culture system and future studies
will need to address this mechanistic question. Most likely
this biological inquiry will need to be answered at a single
cell level in future studies.
While this study has some limitations, reactivation strate-
gies hold great promise for individuals suffering from X-
linked disorders. In contrast to pharmacological inhibi-
tion of DNMT1, which postulates the need for mitosis,
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TET1CD might be a promising tool for demethylation in
quiescent tissues that have been traditionally more difficult
to target, such as the brain (27). In addition, superactiva-
tion by VP64 of the already active CDKL5 allele needs to
be carefully assessed due to the fact that Xp22 duplica-
tions containing the CDKL5 gene have been described as
pathogenic variants (65). Interestingly, we and others have
identified that epigenetic editing using dCas9-TET1 does
not exceed super-physiological levels of an X-linked target
gene, further making this approach favorable in the light
of a dosage sensitive gene. Future studies will have to as-
sess what the biological consequence of the achieved escape
level is on the gene and protein level inmore disease-relevant
models such as patient-derived iPSC-neurons, organoids,
and animal models.
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